March 28, 2011

HELIX BIOPHARMA ANNOUNCES $3.9 MILLION PRIVATE PLACEMENT (PDF)

AURORA, Ontario, MARCH 28, 2011 Helix BioPharma Corp. (“Helix” or the “Company”) (TSX, NYSE Amex, FSE:
“HBP”), a developer of biopharmaceutical drug candidates for the prevention and treatment of cancer, today announced that it has received subscriptions for the purchase, by way of private placement, of 1,652,719 units of the Company at $2.39 per unit.